This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matsui, T. Articles by Fujita, T. Search for Related Content PubMed PubMed Citation Articles by Matsui, T. Articles by Fujita, T.

1,25-Dihydroxyvitamin D₃-regulated Expression of Genes Involved in Human T-Lymphocyte Proliferation and Differentiation¹

Third Division, Departments of Medicine [T. M., Y. N., T. K., Y. K., T. F.] and Pathology [R. T., T. S.], Kobe University School of Medicine, Kobe 650, and Institute for Virus Research, Kyoto University [K. M.], Kyoto 606, Japan

1,25-Dihydroxyvitamin D₃ [1,25-(OH)₂D₃] inhibited the secretion of -interferon from human T-lymphocytes activated by the calcium ionophore, A23187, or phytohemagglutinin with or without 12-O-tetradecanoylphorbol-13-acetate. The agent also inhibited cell proliferation and interleukin 2 secretion by these cells. The inhibition of -interferon secretion was time and dose dependent and partially abolished by the addition of exogenous human recombinant interleukin 2. To elucidate the molecular events by which 1,25-(OH)₂D₃ inhibits cell proliferation and lymphokine secretion, complementary DNA probes were used to follow the expression of genes involved in human T-lymphocyte proliferation and differentiation. 1,25-(OH)₂D₃ inhibited the expression of interleukin 2 and -interferon messenger RNA in human lymphocytes activated by phytohemagglutinin and 12-O-tetradecanoylphorbol-13-acetate. It also inhibited the accumulation of c-myc protooncogene messenger RNA and, to a lesser extent, interleukin 2 receptor messenger RNA in these cells. However, it did not affect the expression of the HLA-DR gene. These results suggest that 1,25-(OH)₂D₃ selectively regulates T-lymphocyte activation-related genes at the level of messenger RNA.

¹ This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture and by a grant for cancer research from the Ministry of Health and Welfare of Japan.

² To whom requests for reprints should be addressed.

Received 12/19/85. Revised 5/ 1/86. Accepted 7/17/86.

This article has been cited by other articles:

				S. Nagpal, S. Na, and R. Rathnachalam Noncalcemic Actions of Vitamin D Receptor Ligands Endocr. Rev., August 1, 2005; 26(5): 662 - 687. [Abstract] [Full Text] [PDF]

				M. Cippitelli, C. Fionda, D. Di Bona, F. Di Rosa, A. Lupo, M. Piccoli, L. Frati, and A. Santoni Negative Regulation of CD95 Ligand Gene Expression by Vitamin D3 in T Lymphocytes J. Immunol., February 1, 2002; 168(3): 1154 - 1166. [Abstract] [Full Text] [PDF]

				T. P. Staeva-Vieira and L. P. Freedman 1,25-Dihydroxyvitamin D3 Inhibits IFN-{gamma} and IL-4 Levels During In Vitro Polarization of Primary Murine CD4+ T Cells J. Immunol., February 1, 2002; 168(3): 1181 - 1189. [Abstract] [Full Text] [PDF]

				A. Takeuchi, G. S. Reddy, T. Kobayashi, T. Okano, J. Park, and S. Sharma Nuclear Factor of Activated T Cells (NFAT) as a Molecular Target for 1{alpha},25-Dihydroxyvitamin D3-Mediated Effects J. Immunol., January 1, 1998; 160(1): 209 - 218. [Abstract] [Full Text] [PDF]